Patents Assigned to Rosetta Genomics Ltd
  • Publication number: 20190241966
    Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Application
    Filed: December 19, 2018
    Publication date: August 8, 2019
    Applicant: Rosetta Genomics Ltd.
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald
  • Patent number: 10301627
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: May 28, 2019
    Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Publication number: 20190032142
    Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 31, 2019
    Applicant: Rosetta Genomics Ltd.
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald, Nir Dromi
  • Publication number: 20190010491
    Abstract: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods ad compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
    Type: Application
    Filed: January 16, 2018
    Publication date: January 10, 2019
    Applicant: Rosetta Genomics Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Publication number: 20180127835
    Abstract: The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 10, 2018
    Applicant: Rosetta Genomics Ltd.
    Inventors: Ranit Aharonov, Nitzan Rosenfeld, Shai Rosenwald
  • Publication number: 20180127755
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Application
    Filed: November 15, 2017
    Publication date: May 10, 2018
    Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 9845470
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 19, 2017
    Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 9803247
    Abstract: The present invention provides a process for classification of specific cancers and tumors origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: October 31, 2017
    Assignees: Rosetta Genomics, Ltd., Tel Hashomer Medical Infrastructure and Services Ltd.
    Inventors: Nitzan Rosenfeld, Shai Rosenwald, Iris Barshack, Dvora Nass
  • Patent number: 9765334
    Abstract: Described herein are compositions and methods for survival prediction in gastric cancer patients after surgical operation. The compositions are microRNA molecules associated with the prognosis of gastric cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: September 19, 2017
    Assignees: Rosetta Genomics, Ltd., Mor Research Applications
    Inventors: Moshe Hoshen, Raruch Brenner
  • Publication number: 20170137811
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Application
    Filed: October 26, 2016
    Publication date: May 18, 2017
    Applicants: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 9650680
    Abstract: Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: May 16, 2017
    Assignee: Rosetta Genomics Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 9650679
    Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 16, 2017
    Assignee: Rosetta Genomics Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 9631236
    Abstract: The present invention is based in part on the discovery of a panel of miRs whose levels are increased or decreased in the circulation of chronic systolic HF patients. Accordingly, an extensive panel of miRs was screened in the sera of stable chronic systolic HF patients and the results were compared to an age, gender and ethnically matched control group.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: April 25, 2017
    Assignees: Rosetta Genomics Ltd., MOR Research Applications Ltd.
    Inventors: Yaron Goren, Ofer Amir
  • Patent number: 9624556
    Abstract: Described herein are novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of viral infections.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 18, 2017
    Assignee: Rosetta Genomics Ltd.
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 9540695
    Abstract: Described herein are compositions and methods for the prediction of the prognosis of ovarian cancer subjects. The present invention further provides methods for distinguishing between histological subtypes of ovarian cancer tumors, and also methods and compositions for the treatment or prevention of ovarian cancer. Specifically the invention relates to microRNA molecules associated with said methods and compositions, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: January 10, 2017
    Assignees: Rosetta Genomics Ltd., MOR Research Applications
    Inventors: Moshe Hosen, Gila Lithwick Yanai, Ram Eitan
  • Patent number: 9506062
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: November 29, 2016
    Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 9487781
    Abstract: The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 8, 2016
    Assignee: Rosetta Genomics Ltd.
    Inventor: Noga Yerushalmi
  • Patent number: 9340823
    Abstract: The present invention provides a method for classification of kidney tumors through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: May 17, 2016
    Assignees: Rosetta Genomics, Ltd., Tel Hashomer Medical Research Infrastructure and Services Ltd.
    Inventors: Nitzan Rosenfeld, Yael Spector, Eddie Friedman, Zohar Dotan
  • Patent number: 9334540
    Abstract: The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: May 10, 2016
    Assignees: Rosetta Genomics Ltd., MOR Research Applications
    Inventors: Yaron Goren, Shlomit Gilad, Moshe Hod, Yariv Yogev
  • Patent number: 9243296
    Abstract: Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 26, 2016
    Assignee: Rosetta Genomics Ltd.
    Inventors: Ayelet Chajut, Shai Rosenwald